China Health Technology Group Rights Issue 2026: Provisional Allotment, Subscription Instructions, and Key Dates

China Health Technology Group Announces Major Rights Issue: What Investors Need to Know

China Health Technology Group Holding Company Limited (Stock Code: 1069) has issued a detailed Provisional Allotment Letter (PAL) to shareholders regarding a significant Rights Issue. This corporate action is set to impact shareholder value and could influence the company’s share price in the coming weeks. Below, we break down the critical aspects of the announcement, potential implications for share value, and essential actions for investors.

Key Points of the Rights Issue

Rights Issue Details: Shareholders are offered the opportunity to subscribe for new shares at a ratio of two (2) Rights Shares for every one (1) existing share held as of the Record Date, 22 May 2026.
Subscription Price: The price is set at HK\$0.25 per Rights Share. This discounted price could be attractive to shareholders and may affect trading activity and share valuation.
Acceptance Deadline: Shareholders must accept their rights and submit payments by 4:00 p.m. on Tuesday, 9 June 2026. Delays or bad weather/extreme conditions may extend the deadline as outlined in the PAL.
Non-Underwritten Basis: The Rights Issue will proceed regardless of the level of subscription. If not fully subscribed, unsold Rights Shares will be placed with independent placees. Any Rights Shares not placed will not be issued, reducing the size of the Rights Issue.
No Minimum Subscription: There is no statutory minimum amount to be raised, nor a minimum subscription level required.
Eligibility: Only Qualifying Shareholders are entitled to participate. The PAL and Prospectus are distributed only to them.
Share Ranking: Rights Shares, once allotted and fully paid, will rank pari passu with existing shares, entitling holders to future dividends and distributions.

Details Investors Must Pay Attention To

Payment Instructions: Subscriptions must be made by cheque or banker’s cashier order in Hong Kong dollars, drawn on a licensed Hong Kong bank. Payments should be made to “China Health Technology Group Holding Company Limited – PAL Account” and crossed “Account Payee Only”.
Transfer and Splitting: Shareholders can transfer all or part of their rights, or split their allotment by surrendering the original PAL for new PALs by 4:30 p.m. on Monday, 1 June 2026. This enables flexibility in managing entitlements or selling/transferring rights.
Stamp Duty: Hong Kong ad valorem stamp duty is payable on both the sale and purchase of Rights, and evidence of payment is required for registration of any transfer.
Scale-Down Mechanisms: To avoid triggering a Mandatory General Offer (MGO) or breaching public float requirements, applications may be scaled down by the company with refunds issued as appropriate. This is key for major shareholders and those acting in concert.
Trading of Rights Shares: Rights Shares in nil-paid form will trade from 28 May 2026 to 4 June 2026. Shareholders dealing in these instruments before the Rights Issue becomes unconditional (expected by 7 July 2026) bear the risk of reversal if conditions are not met.
Refunds and Share Certificates: Share certificates for fully-paid Rights Shares and refund cheques, if applicable, will be posted on or before 17 June 2026.

Potential Price-Sensitive Implications

Discounted Pricing: The subscription price (HK\$0.25 per share) is likely below the current market price, which could incentivise participation and potentially dilute share value if not fully subscribed.
Non-Underwritten Structure: The absence of a minimum subscription or underwriting means the Rights Issue could be partially subscribed, resulting in fewer new shares issued and impacting capital raising plans.
Impact on Public Float and MGO: The scaling down of applications to avoid regulatory breaches could affect the distribution of shares and ownership structure, potentially influencing share liquidity and trading patterns.
Risk Factors: The PAL warns that dealing in shares and nil-paid rights carries risks, especially if the Rights Issue fails to become unconditional. Investors should exercise caution and consult professional advisers.

Additional Investor Considerations

Personal Data: By participating, shareholders agree to disclose personal data per Hong Kong’s Personal Data (Privacy) Ordinance. Data access and corrections are available upon request, subject to administrative fees.
Jurisdictional Restrictions: The Rights Issue is only offered to Qualifying Shareholders in Hong Kong. Those outside Hong Kong must ensure compliance with local laws before participating.
No Fractional Entitlements: Fractional Rights Shares will not be issued; the allotment is strictly two Rights Shares per one existing share.
Timetable Risks: The acceptance deadline may be extended in case of bad weather or “extreme conditions,” with updates provided by company announcements.

Conclusion: Why This Matters for Shareholders

This Rights Issue represents a major corporate action by China Health Technology Group, offering shareholders a chance to increase their stake at a discounted price. However, the non-underwritten nature, potential dilution, and regulatory considerations make this a price-sensitive event that could move the share price, depending on investor demand and subscription levels. Shareholders should carefully review the PAL and Prospectus, ensure timely payment, and assess their position regarding transfer, splitting, and potential dilution.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should consult their own professional advisers regarding participation in the Rights Issue and assess all risks and personal circumstances before acting.

中國健康科技集團發行重大供股權：投資者須知

中國健康科技集團控股有限公司（股份代號：1069）向股東發出詳細的臨時分配通知書（PAL），涉及一項重要供股權。這項公司行動有望影響股東價值，並可能在未來幾週內影響股價。以下為供股權公告的重點、潛在影響及投資者需採取的行動。

供股權主要內容

供股詳情：股東可按每持有一股現有股份可認購兩股供股股份的比例參與，記錄日為2026年5月22日。
供股價：每股供股股份港幣0.25元。此折扣價可能對股東有吸引力，並影響交易活動及股價。
接受截止日期：股東必須在2026年6月9日（星期二）下午4時前接受供股權並付款。如有惡劣天氣或極端情況，截止日期可能延長。
非包銷：無論供股認購情況如何，供股權將繼續進行。若未被全部認購，未售出的供股股份將以最佳努力方式配售予獨立配售對象，未配售股份則不予發行，供股規模將相應減少。
無最低認購：本次供股無法定最低募資額或最低認購水平要求。
資格：只有合資格股東可參與，PAL及招股書僅向他們發送。
股份排名：供股股份一旦配發及全額繳付，將與現有股份同等排名，可享所有未來派息及分派。

投資者需注意事項

付款指示：認購須以港元支票或銀行本票支付，並須於香港持牌銀行開立，付款至「中國健康科技集團控股有限公司PAL戶口」並標註「只收款戶」。
權利轉讓與分拆：股東可將全部或部分權利轉讓或分拆，須於2026年6月1日（星期一）下午4時30分前交回原PAL，由登記處辦理分拆。
印花稅：供股權轉讓及接受均須繳納香港從價印花稅，轉讓登記須提供繳稅證明。
縮減機制：為避免觸發強制全面收購（MGO）或違反公眾持股量規定，供股申請會被公司縮減至合規水平，多付認購款項將獲退款。
供股股份交易：供股股份於2026年5月28日至6月4日以「未繳股」形式交易。供股條件尚未落實（預計2026年7月7日），股東承擔供股未能落實的風險。
退款及股份證書：全額供股股份證書及退款支票（如適用）預計於2026年6月17日或之前郵寄。

潛在價格敏感事項

折扣供股價：認購價（港幣0.25元）或低於現價，可能刺激認購並造成股份稀釋，若未能全部認購，影響集資計劃。
非包銷結構：未設最低認購，供股或部分認購，影響新股發行數量及資本結構。
公眾持股及MGO風險：縮減申請影響股份分布及持股結構，可能影響流動性及交易。
風險警告：PAL提醒，供股條件未落實前，股份及「未繳股」交易存在風險，投資者應謹慎行事及諮詢專業意見。

額外投資者須知

個人資料：參與時須披露個人資料，根據《個人資料（私隱）條例》可申請查閱及更正，需支付行政費。
司法管轄限制：供股僅向香港合資格股東發行，海外股東須遵守當地法律。
無零碎權益：供股分配嚴格按二股一股，不會產生零碎供股股份。
時間表風險：如遇惡劣天氣，接受截止日可能延長，公司會公告最新情況。

總結：供股權對股東意味著甚麼

今次供股權為中國健康科技集團重大公司行動，股東可低價增持股份。惟非包銷、潛在稀釋及合規考慮使此供股成為價格敏感事件，股價或受認購需求及參與水平影響。股東應詳細閱讀PAL及招股書，按時付款，並慎重考慮轉讓、分拆及稀釋風險。

免責聲明

本文僅供參考，不構成投資建議。投資者應諮詢專業顧問，根據自身情況及風險評估決定是否參與供股權。